Greenwich LifeSciences (GLSI) EBT (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of EBT data on file, last reported at -$17.2 million in Q4 2025.

• Quarterly EBT fell 5.48% year-over-year to -$17.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.6 million (down 19.04% YoY) and the FY2025 annual result came in at -$28.6 million, down 19.04% from the prior year.
• EBT declined to -$17.2 million in Q4 2025, from -$4.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$597008.0 in Q1 2021 to a low of -$17.2 million in Q4 2025.
• A 5-year average of -$4.4 million and a median of -$3.0 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT sank 511.25% — and 2023, when it soared 44.75%.
• Tracing GLSI's EBT over 5 years: stood at -$3.9 million in 2021, then sank by 52.98% to -$5.9 million in 2022, then fell by 22.34% to -$7.3 million in 2023, then slumped by 124.83% to -$16.3 million in 2024, then fell by 5.48% to -$17.2 million in 2025.
• The last three EBT figures came in at -$17.2 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.